دورية أكاديمية
أعرض في EDS

Risk of Recurrence After Surgical Resection for Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasia (IPMN) With Patterns of Distribution and Treatment: An International, Multicenter, Observational Study (ADENO-IPMN Study).

التفاصيل البيبلوغرافية
العنوان: Risk of Recurrence After Surgical Resection for Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasia (IPMN) With Patterns of Distribution and Treatment: An International, Multicenter, Observational Study (ADENO-IPMN Study).
المؤلفون: Lucocq J; Department of General Surgery, NHS Lothian, UK., Hawkyard J; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK., Robertson FP; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK., Haugk B; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK., Lye J; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK., Parkinson D; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK., White S; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK., Mownah O; Institute of Liver Studies, King's Healthcare Partners, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK., Zen Y; Institute of Liver Studies, King's Healthcare Partners, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK., Menon K; Institute of Liver Studies, King's Healthcare Partners, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK., Furukawa T; Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Inoue Y; Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Hirose Y; Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Sasahira N; Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Feretis M; Cambridge Hepatobiliary and Pancreatic Surgery Unit, Addenbrooke's Hospital, Cambridge, UK., Balakrishnan A; Cambridge Hepatobiliary and Pancreatic Surgery Unit, Addenbrooke's Hospital, Cambridge, UK., Zelga P; Cambridge Hepatobiliary and Pancreatic Surgery Unit, Addenbrooke's Hospital, Cambridge, UK., Ceresa C; Hepatobiliary and Pancreatic Surgery Unit, The Royal Free Hospital, London, UK., Davidson B; Hepatobiliary and Pancreatic Surgery Unit, The Royal Free Hospital, London, UK., Pande R; Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK., Dasari B; Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK., Tanno L; Hepatobiliary and Pancreatic Surgery Unit, University Hospital Southampton, Southampton, UK., Karavias D; Hepatobiliary and Pancreatic Surgery Unit, University Hospital Southampton, Southampton, UK., Helliwell J; Hepatobiliary and Pancreatic Surgery Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Young A; Hepatobiliary and Pancreatic Surgery Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Nunes Q; Department of Hepatopancreatobiliary Surgery, East Lancashire Teaching Hospitals NHS Trust, UK., Urbonas T; Oxford Hepato-Pancreato-Biliary (HPB) Surgical Unit, Oxford University Hospitals NHS Foundation Trust, UK., Silva M; Oxford Hepato-Pancreato-Biliary (HPB) Surgical Unit, Oxford University Hospitals NHS Foundation Trust, UK., Gordon-Weeks A; Oxford Hepato-Pancreato-Biliary (HPB) Surgical Unit, Oxford University Hospitals NHS Foundation Trust, UK., Barrie J; Nottingham Hepato-Pancreatico-Biliary (HPB) Service, Nottingham University Hospitals NHS Foundation Trust, UK., Gomez D; Nottingham Hepato-Pancreatico-Biliary (HPB) Service, Nottingham University Hospitals NHS Foundation Trust, UK., van Laarhoven S; Department of General Surgery, University Hospitals Bristol & Weston NHS Foundation trust, UK., Doyle J; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK., Bhogal R; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK., Harrison E; Department of Clinical Surgery, University of Edinburgh, UK., Roalso M; Department of Gastrointestinal Surgery, HPB unit, Stavanger University Hospital, Norway.; Department of Quality and Health Technology, University of Stavanger, Stavanger, Norway., Ciprani D; Hepatopancreatobiliary Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK., Aroori S; Hepatopancreatobiliary Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK., Ratnayake B; Hepato-Pancreatico-Biliary/Upper Gastrointestinal Unit, North Shore Hospital, Auckland, NZ., Koea J; Hepato-Pancreatico-Biliary/Upper Gastrointestinal Unit, North Shore Hospital, Auckland, NZ., Capurso G; San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milan, Italy.; Digestive and Liver Disease Unit, S. Andrea Hospital, Rome, Italy., Bellotti R; Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Austria., Stättner S; Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Austria., Alsaoudi T; Leicester Hepatopancreatobiliary Unit, University Hospitals of Leicester NHS Trust, UK., Bhardwaj N; Leicester Hepatopancreatobiliary Unit, University Hospitals of Leicester NHS Trust, UK., Jeffery F; Department of General and Vascular Surgery, Christchurch Hospital, New Zealand., Connor S; Department of General and Vascular Surgery, Christchurch Hospital, New Zealand., Cameron A; Wolfson Wohl Cancer Research Centre, University of Glasgow, UK., Jamieson N; Wolfson Wohl Cancer Research Centre, University of Glasgow, UK., Sheen A; Department of Anatomical Pathology, New South Wales Health Pathology, Royal North Shore Hospital, Sydney, NSW, Australia., Mittal A; Royal North Shore Hospital, Sydney, NSW, Australia., Samra J; Royal North Shore Hospital, Sydney, NSW, Australia., Gill A; Department of Anatomical Pathology, New South Wales Health Pathology, Royal North Shore Hospital, Sydney, NSW, Australia.; Royal North Shore Hospital, Sydney, NSW, Australia.; Sydney Medical School, University of Sydney, Sydney, NSW, Australia., Roberts K; Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK., Soreide K; Department of Gastrointestinal Surgery, HPB unit, Stavanger University Hospital, Norway.; Department of Clinical Medicine, University of Bergen, Bergen, Norway., Pandanaboyana S; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK.
المصدر: Annals of surgery [Ann Surg] 2024 Jul 01; Vol. 280 (1), pp. 126-135. Date of Electronic Publication: 2023 Oct 24.
نوع المنشور: Journal Article; Multicenter Study; Observational Study
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-1140 (Electronic) Linking ISSN: 00034932 NLM ISO Abbreviation: Ann Surg Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Neoplasm Recurrence, Local*/epidemiology , Pancreatic Neoplasms*/surgery , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/mortality , Pancreatectomy*/methods, Humans ; Male ; Female ; Aged ; Middle Aged ; Adenocarcinoma, Mucinous/surgery ; Adenocarcinoma, Mucinous/pathology ; Adenocarcinoma, Mucinous/mortality ; Carcinoma, Pancreatic Ductal/surgery ; Carcinoma, Pancreatic Ductal/mortality ; Carcinoma, Pancreatic Ductal/pathology ; Retrospective Studies ; Survival Rate ; Adenocarcinoma/surgery ; Adenocarcinoma/pathology ; Adenocarcinoma/mortality ; Pancreatic Intraductal Neoplasms/surgery ; Pancreatic Intraductal Neoplasms/pathology ; Pancreatic Intraductal Neoplasms/mortality
مستخلص: Objective: This international multicenter cohort study aims to identify recurrence patterns and treatment of first and second recurrence in a large cohort of patients after pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasm (IPMN).
Background: Recurrence patterns and treatment of recurrence postresection of adenocarcinoma arising from IPMN are poorly explored.
Methods: Patients undergoing pancreatic resection for adenocarcinoma from IPMN between January 2010 and December 2020 at 18 pancreatic centers were identified. Survival analysis was performed using the Kaplan-Meier log-rank test and multivariable logistic regression by Cox-Proportional Hazards modeling. End points were recurrence (time-to, location, and pattern of recurrence) and survival (overall survival and adjusted for treatment provided).
Results: Four hundred fifty-nine patients were included (median, 70 years; interquartile range, 64-76; male, 54%) with a median follow-up of 78.1 months. Recurrence occurred in 209 patients [45.5%; median time to recurrence, 12.8 months; early recurrence (within 1 years), 23.2%]. Eighty-three (18.1%) patients experienced a local regional recurrence, and 164 (35.7%) patients experienced a distant recurrence. Adjuvant chemotherapy was not associated with reduction in recurrence (hazard ratio 1.09; P =0.669) One hundred twenty patients with recurrence received further treatment. The median survival with and without additional treatment was 27.0 and 14.6 months ( P <0.001), with no significant difference between treatment modalities. There was no significant difference in survival between locations of recurrence ( P =0.401).
Conclusions: Recurrence after pancreatic resection for adenocarcinoma arising from IPMN is frequent with a quarter of patients recurring within 12 months. Treatment of recurrence is associated with improved overall survival and should be considered.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
References: WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. Accessed March 1, 2023]. (WHO classification of tumours series, 5th ed. https://tumourclassification.iarc.who.int/chapters/31.
Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17:738–753.
Kim HS, Han Y, Kang JS, et al. Fate of patients with intraductal papillary mucinous neoplasms of pancreas after resection according to the pathology and margin status: continuously increasing risk of recurrence even after curative resection suggesting necessity of lifetime surveillance. Ann Surg. 2022;276:e231–e238.
Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011;60:509–516.
Hirono S, Shimizu Y, Ohtsuka T, et al. Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol. 2020;55:86–99.
Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, et al. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. J Am Coll Surg. 2011;213:275e83.
Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788e97.
Marchegiani G, Andrianello S, Dal Borgo C, et al. Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. HPB (Oxford). 2019;21:596–603.
Yamada S, Fujii T, Hirakawa A, et al. Comparison of the survival outcomes of pancreatic cancer and intraductal papillary mucinous neoplasms. Pancreas. 2018;47:974–979.
Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut. 2002;51:717–722.
Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143:639–646.
Ratnayake B, Savastyuk AY, Nayar M, et al. Recurrence patterns for pancreatic ductal adenocarcinoma after upfront resection versus resection following neoadjuvant therapy: a comprehensive meta-analysis. J Clin Med. 2020;9:2132.
Murakami Y, Uemura K, Sudo T, et al. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol. 2009;100:13–18.
von Elm E, Altman DG, Egger M, et al; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349.
Turrini O, Waters JA, Schnelldorfer T, et al. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. HPB (Oxford). 2010;12:447–455.
Hank T, Hinz U, Tarantino I, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br J Surg. 2018;105:1171–1181.
Schober P, Boer C, Schwarte L. Correlation coefficients: appropriate use and interpretation. Anesthesia & Analgesia. 2018;126:1763–1768.
Elta GH, Enestvedt BK, Sauer BG, et al. ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol. 2018;113:464–479.
Swartz MJ, Hsu CC, Pawlik TM, et al. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys. 2010;76:839–844.
Caponi S, Vasile E, Funel N, et al. Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms. Eur J Surg Oncol. 2013;39:396–403.
Moletta L, Serafini S, Valmasoni M, et al. Surgery for recurrent pancreatic cancer: is it effective? Cancers (Basel). 2019;11:991.
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024.
Kaiser J, Scheifele C, Hinz U, et al. IPMN-associated pancreatic cancer: survival, prognostic staging and impact of adjuvant chemotherapy. Eur J Surg Oncol. 2022;48:1309–1320.
European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67:789–804.
Chong E, Ratnayake B, Dasari BVM, et al. Adjuvant Chemotherapy in the Treatment of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Systematic Review and Meta-Analysis. World J Surg. 2022;46:223–234.
McMillan MT, Lewis RS, Drebin JA, et al. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). Cancer. 2016;122:521–533.
Rodrigues C, Hank T, Qadan M, et al. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020;20:722e8.
Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503–3510.
Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol. 2008;26:3511–3516.
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
Noë M, Niknafs N, Fischer CG, et al. Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nat Commun. 2020;11:4085.
Daamen LA, Groot VP, Intven MPW, et al; Dutch Pancreatic Cancer Group. Postoperative surveillance of pancreatic cancer patients. Eur J Surg Oncol. 2019;45:1770–1777.
تواريخ الأحداث: Date Created: 20231024 Date Completed: 20240607 Latest Revision: 20240607
رمز التحديث: 20240607
DOI: 10.1097/SLA.0000000000006144
PMID: 37873663
قاعدة البيانات: MEDLINE
الوصف
تدمد:1528-1140
DOI:10.1097/SLA.0000000000006144